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Abstract: Withania somnifera (Ashwagandha) is an Ayurvedic herb categorized as having “rasayana”
(rejuvenator), longevity, and revitalizing properties. Sensoril®is a standardized aqueous extract of the
roots and leaves of Withania somnifera. Purpose: To examine the impact of Sensoril® supplementation
on strength training adaptations. Methods: Recreationally active men (26.5 ± 6.4 years, 181 ± 6.8 cm,
86.9 ± 12.5 kg, 24.5 ± 6.6% fat) were randomized in a double-blind fashion to placebo (PLA, n = 19)
or 500 mg/d Sensoril® (S500, n = 19). Body composition (DEXA), muscular strength, power, and
endurance, 7.5 km cycling time trial, and clinical blood chemistries were measured at baseline and
after 12 weeks of supplementation and training. Subjects were required to maintain their normal
dietary habits and to follow a specific, progressive overload resistance-training program (4-day/week,
upper body/lower body split). 2 × 2 mixed factorial ANOVA was used for analysis and statistical
significance was set a priori at p ≤ 0.05. Results: Gains in 1-RM squat (S500: +19.1 ± 13.0 kg vs. PLA
+10.0 ± 6.2 kg, p = 0.009) and bench press (S500: +12.8 ± 8.2 kg vs. PLA: +8.0 ± 6.0 kg, p = 0.048)
were significantly greater in S500. Changes in DEXA-derived android/gynoid ratio (S500: +0.0 ± 0.14
vs. PLA: +0.09 ± 0.1, p = 0.03) also favored S500. No other between-group differences were found for
body composition, visual analog scales for recovery and affect, or systemic hemodynamics, however,
only the S500 group experienced statistically significant improvements in average squat power,
peak bench press power, 7.5 km time trial performance, and perceived recovery scores. Clinical
chemistry analysis indicated a slight polycythemia effect in PLA, with no other statistical or clinically
relevant changes being noted. Conclusions: A 500 mg dose of an aqueous extract of Ashwagandha
improves upper and lower-body strength, supports a favorable distribution of body mass, and
was well tolerated clinically in recreationally active men over a 12-week resistance training and
supplementation period.
Keywords: Ashwaganhda; Ayurvedic; resistance training; exercise; placebo; strength; DEXA

1. Introduction
Withania somnifera (ashwagandha) is an Ayurvedic herb belonging to the Solanaceae family.
Previous reports have categorized Withania somnifera as having “rasayana” (rejuvenator), longevity, and
revitalizing properties [1–3], but these reports have yet to be fully substantiated using well-controlled,
scientific investigations. Ashwagandha has previously been studied in therapeutic areas surrounding
cognitive, mood, psychomotor, joint health [2], antioxidation [3], and anti-inflammation. While a firm
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understanding of many mechanisms of action is not yet present, ashwagandha contains bioactive
compounds, including alkaloids (withanine, withasomnin), lactones (withanolides), and glycosides
(sitoindosides) that may account for these purported physiological effects [1]. Ashwaganda has also
been recognized as having “adaptogenic” properties, which may support a favorable response to the
physical and mental stressors of a high-intensity exercise program [1]. Human clinical and animal
data in dosages, ranging from 250 to 1000 mg/day, suggest that there is a wide range of physiological
effects that may lead to ergogenic benefits, including but not limited to: anxiolytic [4], analgesic [5],
anti-inflammatory, anabolic, cardiopulmonary, and antioxidant effects [6]. However, it is important to
note that the composition of different Withania somnifera extracts depend upon which type of extraction
method is used and what part of the plant is undergoing the extraction technique [7]. Limited research
has examined the impact of root extracts or other combinations of the plant for their impact on
various outcomes.
Sandhu and colleagues [6] were some of the first researchers to examine if Ashwagandha
supplementation exerted any impact on muscular or aerobic performance parameters. Using a
placebo-controlled approach, 10 healthy participants were assigned to consume either a placebo or
Ashwagandha (500 mg/day) for 10 days, and were assessed for changes in power, balance, and
maximal oxygen consumption (VO2 Max). Within-group changes revealed that barbell velocity, power,
and VO2 Max were all increased after ashwagandha supplementation, but no such change was found
to occur in the placebo group. The supplement was well tolerated, with no reported adverse events.
A later study by Raut et al. [8] enrolled 18 healthy volunteers who were provided increasing dosages
of Ashwagandha for a total of 30 days (10 days consecutively at 750 mg/day, 1000 mg/day and,
1250 mg/day) in a prospective, open-label design. All participants were assessed for adverse events as
well as changes in strength, exercise tolerance, and body composition using skinfolds. Ashwagandha
supplementation was found to reduce total and low-density lipoprotein (LDL) cholesterol and increase
muscle strength. Further, body composition tended to improve during the study. Most recently,
Wankhede and colleagues [9] reported data on the impact of ashwagandha supplementation (300 mg
of root extract, 2×/day) in 57 young, untrained male participants. All participants completed an 8-week
course of resistance training while supplementing daily, and had their strength, body composition,
and muscle recovery assessed. In these untrained participants taking a root extract of ashwagandha,
muscle strength was significantly increased in both the upper-body and lower-body, changes in muscle
size using circumference measurements in the arms and chest were greater than changes seen in the
placebo group, and reductions in body fat percentage (measured with bioimpedance) were greater in
the ashwagandha supplemented group. Additionally, blood markers of damage and recovery, and
basal testosterone levels were also slightly improved in the participants taking ashwagandha.
While emerging research has begun to highlight the potential ability of ashwagandha
supplementation to improve adaptations seen while resistance training, many studies highlighted
above either recruited relatively small numbers of participants or only supplemented for relatively
brief periods (<30 days) of time. With the exception of the Wankhede et al. [9] investigation, no research
has supplemented with higher dosages while participants completed resistance training for longer than
eight weeks. Consequently, more research is needed that span longer supplementation and exercise
training protocols in additional study populations at dosages used in previous studies than that
supplemented with higher dosages (≥500 mg/day). Furthermore, limited research has explored the
impact of an aqueous extract of ashwagandha of both roots and leaves of the native plant. Sensoril® is
a standardized aqueous extract of the roots and leaves of Withania somnifera, and it contains glycosides,
Withaferin-A, and oligosaccharides as major bioactive components. The purpose of this study was to
examine the impact of a 500 mg dose of Sensoril® supplementation vs. placebo in recreationally active
participants over a 12-week resistance training and supplementation protocol. Primary outcomes
were changes in muscle strength and secondary measures were changes in body composition, visual
analog scales for recovery and affect, muscle endurance, and power. Based on previous research,
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it was hypothesized that ashwagandha supplementation would significantly improve muscle strength
versus placebo.
2. Materials and Methods
2.1. Overview of the Study Design
The study design employed for this protocol was a randomized, double-blind, placebo-controlled
investigation that spanned 12 weeks. Each participant completed four study visits (Table 1). The first
visit was for screening purposes, and consisted of signing an IRB-approved consent form (IntegReview,
Austin, TX, USA; Protocol number: NATSEN-STAR-001-2017; approval date: 19 July 2017) that
was in accordance with the Declaration of Helsinki, completing a medical history, recording dietary
information, and assessing routine blood work (comprehensive metabolic panel (CMP), complete
blood count (CBC), lipid panel). During the second visit, participants were familiarized with the testing
protocols used in the study. To evaluate clinical safety, participants had hemodynamic, complete blood
counts, comprehensive metabolic, and lipid panels completed after 0 (visit 3) and 12 weeks (visit
4) of supplementation and resistance training. Body composition, dietary habits, upper-body and
lower-body strength, power, and endurance, 7.5 km cycling time trial, and various recovery and visual
analog scales to assess fatigue/energy, mood, quality of training, and motivation to exercise, were
all assessed after 0 and 12 weeks of supplementation. Supplements were consumed once daily in
the morning with cold tap water. Prior to all study visits, participants were asked to replicate their
previous 24 h dietary intake, abstain from exercise for 48 h and fast for ten hours. Figure 1 provides a
CONSORT (Consolidated Standards of Reporting Trials) flow diagram of the study.
Table 1. Overview of research design.
Procedure
Informed Consent
Inclusion/Exclusion Criteria
Medical History
Physical
Height, weight, BP, HR
Safety Screen (CMP, CBC, lipid panel)
Informed Consent
24 h Diet Recall
DEXA–Body Composition
Visual Analog Scales/PRS
Strength, Endurance, and Power
7.5 km Time Trial
3-Day Diet Records/Analysis
Protocol Compliance (pill counts and log check)
Adverse Events Monitoring

Visit 1
Screening
X
X
X
X
X
X
X
X

Visit 2
Practice

Visit 3
(Week 0)

Visit 4
(Week 12)

X

X
X

X
X

X
X
X
X
X
X
X

X
X
X
X
X
X
X

X
X
X

X

X

X = procedure performed, BP = Blood pressure; HR = heart rate; CMP = Comprehensive metabolic panel; CBC =
Complete blood counts; DEXA = Dual-energy X-ray absorptiometry; PRS = Perceived recovery status.

Figure 1. CONSORT Diagram
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Assessed for eligibility (n = 47)

Excluded (n=7)
 Not meeting inclusion criteria (n =

Randomized (n = 40)

Allocation
S500: Allocated to intervention (n = 19)

PLA: Allocated to intervention (n = 21)



Received allocated intervention (n = 19)



Received allocated intervention (n = 21)



Did not receive allocated intervention (n = 0)



Did not receive allocated intervention (n = 0)

Follow-Up
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)

Lost to follow-up (n = 2)
 No show (n = 1)
 Did not return calls (n = 1)
Discontinued intervention (n = 0)

Analysis
Analyzed (n=19)

Analyzed (n = 19)

 Excluded from analysis (n = 0)



Excluded from analysis (n = 0)

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.

2.2. Study Participants
Male study participants (n = 40) between the ages of 18–45 years (26.3 ± 6.7 years, 1.80 ± 0.07 m,
87.0 ± 12.8 kg) were recruited from the local community in Stow, OH. All participants read
and signed an IRB-approved informed consent (IntegReview, Austin, TX, USA; Protocol number:
NATSEN-STAR-001-2017; approval date: 19 July 2017) form, that was in accordance with the
Declaration of Helsinki, prior to their participation in the study. Upon a review of health/medical
history documents and physical exam by a study physician, all study participants were determined to
be apparently healthy, recreationally active (training no more than 2–3 days/week for 6–12 months).
After screening, all participants had body mass index values between 20–35 kg/m2 , were normotensive
(≤140/≤90 mmHg) and had a normal resting heart rate (≤90 beats/min). Each participant verbally
denied using any dietary supplement or finished product (i.e., a pre-workout supplement) that is
considered to be ergogenic (i.e., creatine, HMB, beta-alanine, beetroot, phosphates, etc.) in the four
weeks prior to screening, as well as during study. Use of a standard strength multivitamin was allowed.
2.3. Participant Demographics
Standing height was determined using a wall-mounted stadiometer with each study participants
in socks with heels together. Body weight was measured using a Seca 767TM Medical Scale (Hamburg,
Germany, Deutschland). Resting heart rate and blood pressure were measured in duplicate using an
automated blood pressure cuff (Omron HEM-780).
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2.4. Venous Blood Collection
Venous blood samples were collected using standard phlebotomy techniques after 0 and 12 weeks
of supplementation and resistance training.
Whole blood samples were collected into
K2 -Ethylenediaminetetraacetic acid (EDTA) treated Vacutainer tubes and upon collection were slowly
inverted 10 consecutive times prior to immediate refrigeration. Serum samples were collected in
serum separator tubes and allowed to clot for 30 min at room temperature prior to being centrifuged
(Horizon mini E Centrifuge, Drucker Diagnostics, Port Matilda, PA, USA) for 15 min at 3200 rpm
(1600× g). All blood samples were analyzed for clinical chemistry analysis (glucose, blood urea
nitrogen (BUN), creatinine, aspartate aminotransaminase (AST), alanine aminotransaminase (ALT),
creatine kinase, lactate dehydrogenase, total bilirubin, alkaline phosphatase (ALP), triglycerides
(TG), total cholesterol (TC), low -density lipoprotein (LDL), very low-density lipoprotein (VLDL),
high-density lipoprotein (HDL), uric acid, sodium, potassium, total protein, albumin, globulin, iron,
complete blood cells, and platelet count) using automated clinical chemistry analyzers (LabCorp,
Dublin, OH, USA). All samples from the same day were batch-analyzed with test-retest reliabilities
commonly reported using internal quality control data from clinical laboratories and associated
automated analyzers within a range of 3–5% [10].
2.5. Body Composition
Lean mass, fat mass, percentage of fat, and android/gynoid ratio were determined by dual-energy
x-ray absorptiometry (DEXA; General Electric Lunar DPX Pro) after 0 and 12 weeks of supplementation
and resistance training. All DEXA scans were performed by the same technician and analyzed by
the manufacturer’s software (enCORE version 13.31, General Electric Healthcare Lunar, Madison,
WI, USA); reliability assessments using our device and protocol have been published previously [11].
Briefly, subjects were positioned in the scanner according to standard procedures, and remained
motionless for approximately 15 min during scanning. DEXA segments for the upper and lower
limbs and trunk were directed using standard anatomical landmarks. Percent fat was calculated
by dividing the fat mass by the total scanned mass. Lean-to-fat mass ratio was computed using a
simple ratio between the two values. Using the previously defined scanning regions and anatomical
landmarks, the android region was defined in the software as the trunk and torso region, while the
gynoid region was demarcated by the hip region. From here, android-to-gynoid ratio was computed
from the manufacturer software using the pre-defined regions and segments outlined as part of the
analysis procedures. Quality control calibration procedures were performed prior to all scans using a
calibration block and procedures provided by the manufacturer. Prior to this study, we determined
the test–retest reliability for repeated measurements of lean mass, bone mineral content, and fat mass
using this DEXA using intra-class correlation coefficients (ICC); all values were ≥0.98 [11].
2.6. Muscular Strength
Using standard NSCA (National Strength and Conditioning Association) protocols [12],
one-repetition maximum (1-RM) using the Smith machine bench press and back squat were determined
as an indicator of maximal upper body and lower body strength, respectively. All maximal attempts
were supervised by trained research personnel. Each repetition of the bench press was considered a
good repetition if five points of contact (both feet, hips, shoulders, head) were maintained at all points
in time and the bar touched the participant’s chest before fully extending the elbows. Similarly, squat
repetitions were supervised and spotted, and each repetition was required to go down to a depth
where the bottom of the thigh was parallel to the ground. Each subject first performed a warm-up set
of eight repetitions at approximately 50% of the perceived 1-RM followed, by a set of three repetitions
at 70% of the perceived 1-RM. Thereafter, the subject performed single lifts at progressively heavier
weights until failure. No more than five maximal attempts were completed in one testing session.
The maximal weight achieved for both the bench press and back squat exercise using these procedures
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was considered as their 1 RM. Three minutes of rest were given between each maximal attempt,
and four minutes rest was given after 1-RM determination before beginning the next assessment.
The reliability of these strength testing procedures has been previously determined (ICC, r = 0.994,
unpublished data).
2.7. Muscular Power
Upper and lower-body power were assessed through the completion of a Smith machine bench
press (at 65% of each subject’s 1 RM), and a body weight jump squat while connected a TENDO power
analyzer. Previous studies have incorporated the use of a TENDO into their study design [13], and
Stock and colleagues [14] have published data to indicate that it is a reliable means of assessment.
Reliability in our hands for jump squats (ICC, r = 0.926) and jump throws (ICC, r = 0.921) has been
previously determined (unpublished data). The unit consists of a position transducer that measures
the rate of linear displacement, providing velocity and acceleration in addition to power production.
During the bench press exercise, the TENDO unit was attached to the end of the Smith machine
bar. Subjects laid flat on their backs on a bench with their feet on the ground and hands on the bar
in a pronated grip. Grip width was standardized for all subjects and reproduced during follow-up
testing. Subjects lowered the bar (1–2 s eccentric action) until it lightly touched the chest slightly
above the nipple line, and then explosively launched the bar vertically upwards. During the back
squat exercise, participants had a TENDO tethered to their waist using a belt before completing three
countermovement jumps. For each jump, subjects were required to bend their elbows and place their
hands on their hips. Each jump was recorded for peak power and average power. The average of all
three collected values for each variable was calculated and used for statistical analysis. Approximately
60–90 s of rest was given between repetitions, and three minutes rest was provided after the completion
of the third jump.
2.8. Muscular Endurance
To assess upper-body muscular endurance, approximately 65% of the participant’s 1-RM was
then loaded onto the bar and each participant was instructed to complete as many repetitions as
possible. Each subject completed a total of three sets, interspersed with 60 s of rest. A repetition
was only counted if a full range of motion was attained, and once a participant began the set they
could not rest for any longer than two seconds at any point throughout the set. The total number of
repetitions completed were used as a measure of upper body muscular endurance. Following the
third set, a three minute rest period was given before completing the next assessment. Using identical
procedures, participants then had their 1-RM determined on the back-squat exercise before resting for
four minutes and completing the muscular endurance protocol mentioned above (i.e., 3 sets × as many
reps as possible), using the back squat exercise to assess lower-body muscular endurance. The total
number of repetitions performed were recorded as their muscular endurance. The reliability of our
test procedures was similar to that previously reported [14,15].
2.9. Aerobic Endurance
All participants were required to complete a 7.5 km time trial on a computerized cycle ergometer
(Velotron, Quarq Technology, Spearfish, SD, USA). Following a 5 min warm up at 75 W, subjects were
instructed to complete the course “as quickly as possible”. Participants self-selected their gear ratio
and cadence and were blinded to all performance information during the trial, except for elapsed
time and distance. All bike measurements (seat height, etc.) and gear selections were recorded and
replicated for subsequent follow-up testing. Subjects were permitted to drink water ad libitum during
the test. The reliability of the Velotron to determine anaerobic power has been previously reported [16].
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2.10. Visual Analog Scales
Visual analog scales (VAS) were completed by study participants after 0 and 12 weeks of
supplementation and resistance training. All VAS were constructed similarly with a 100 mm line
anchored by the “Lowest Possible” and “Highest Possible” to assess subjective ratings of mood, desire
to workout, willingness to train, optimism, and soreness. The validity and reliability of VAS to assess
fatigue and energy have been previously established [17].
2.11. Dietary Intake and Control
During the initial screening visit, participants were asked to complete a 24 h dietary recall to
assess general habits, food restrictions, and diet composition and intake. Further, 3-day dietary records
were completed prior to visits 3 (week 0) and 4 (week 12), and weekly phone calls were used to track
dietary compliance. Dietary records were analyzed for average daily energy and macronutrient intake
by trained study investigators and NutriBase IX (Clinical Edition) software (CyberSoft, Inc., Phoenix,
AZ, USA). Copies of food records were made and provided to each study participant to allow them to
standardize their dietary and fluid intake prior to visit 4 [18]. No foods or drinks were allowed in the
immediate post-workout period (i.e., 60 min).
2.12. Supplementation
In a randomized, double-blind fashion, participants were assigned to orally ingest either a placebo
or a 500-mg dose of a standardized aqueous extract of the roots and leaves of ashwagandha (Withania
somnifera) (Sensoril® , Natreon, Inc., New Brunswick, NJ, USA). Placebo capsules contained rice flour
and were of identical size and color. All supplements were blinded by the manufacturer prior to
the beginning of the study protocol. The purity and potency of the study product was confirmed by
a third party, an independent laboratory. All doses were taken each morning of the study with 12
fluid ounces of cold tap water. Subjects were matched based on training experience, baseline body
weight, and strength, prior to being randomized into groups using an online randomization program
(www.randomizer.org).
2.13. Resistance Training Program
Upon randomization into a supplementation group, study participants were instructed to follow a
weekly exercise program. The exercise program was a four day per week periodized resistance-training
program designed by a Certified Strength and Conditioning Specialist (CSCS). The workout was
designed to train the upper body and lower body two times/week each on a 4-day split (upper body,
lower body, upper body, lower body) with gradually increasing volume and intensity based off of the
work of Kerksick [19]. The workout consisted of 10–12 exercises, including the following: bench press,
lat pulldown, shoulder press, seated row, shoulder shrug, dip, biceps curl, triceps pushdown, leg
press, squat, deadlift, lunge, leg curl, leg extension, and calf raise. A simple linear periodization was
followed whereby participants trained using three sets of 12–15 RM loads initially and completed the
program using 4–6 sets of eight RM loads. For the bench press exercise, a 1-RM % load assignment was
used, but for all other loads, loading was used according to repetitions maximums, pre-determined
repetition ranges, and following previously instructed loading rules (i.e., 2 × 2 rule). Using this
approach, participants were instructed to increase their weight when they could perform two more
repetitions than what was prescribed on two consecutive sets. Thus, progression was followed and as
strength and endurance improved, training loads were increased to maintain recommended ranges.
Rest periods between exercises were 1–3 min and between sets were 1–2 min. Each daily workout
was not supervised by study investigators; however, study participants were given a training log to
complete for each workout, and each workout was signed off by a training partner or a member of the
fitness staff in addition to being monitored during weekly phone calls.
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2.14. Adverse Events
During weekly phone calls, the frequency and intensity of local and systemic non-serious and
serious adverse events (AEs) were recorded by study team members. All reported events were coded
using the Medical Dictionary for Regulatory Activities (MedDRA), while the intensity of recorded
adverse events were graded using standardized criteria.
2.15. Statistical Analysis
All data were entered into two separate Microsoft Excel spreadsheets (i.e., manual double-key
data entry), and compared to assure data quality prior to analysis. SPSS 23 (Armonk, NY, USA) was
used for all analyses, and data are presented as means ± standard deviations. Normality assumptions
were checked on all variables using a one-sample Shapiro–Wilk test. Non-normal distributions were
transformed using log10 . Outliers were checked via visual inspection of studentized calculations on
the residuals (threshold value of ±3) of each dependent variable. Independent t-tests were used to
assess baseline differences. Data were initially analyzed using 2 × 2 mixed factorial ANOVA (group
(500 mg, PLA) × time (0 vs. 12 weeks)) with repeated measures on time to determine the presence
of any main (time or group) and interaction (group × time) effects. When the sphericity assumption
was not met, the Huynh–Feldt correction was applied. The Mean difference of the change scores and
the 95% confidence intervals were calculated on the difference between groups using delta values.
Within-group effects were compared using a paired samples t-test. Effects were considered to be
significant at p ≤ 0.05, and trends were declared at 0.05 ≤ p ≤ 0.10.
3. Results
Using independent t-tests, no baseline differences (p > 0.05) were noted for any of the demographic
variables (height, body mass, body mass index, body fat %, bench press 1 RM, and squat 1 RM),
except age (p = 0.04) (Table 2). Based on a review of written logs, the overall compliance to the
supplementation and training regimen was 81 and 86%, respectively. Two adverse events occurred
in the placebo group (both arthralgia), and three occurred in the supplement group (1 = arthralgia,
1 = myalgia, 1 = abdominal pain).
Table 2. Study participant demographics and dietary intake.

Age (years)
Height (m)
Body Mass (kg)
Body Mass Index (kg/m2 )
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Resting HR (beats/min)
Squat 1 RM (kg)
Bench Press 1 RM (kg)
DEXA Body Fat (%)

S500
(n = 19)

PLA
(n = 19)

Significance

24.4 ± 4.2
181 ± 6
85.5 ± 10.5
26.2 ± 3.4
124.7 ± 9.7
71.4 ± 7.7
68.4 ± 9.0
105.0 ± 30.2
93.7 ± 21.3
23.8 ± 6.4

28.6 ± 7.6
180 ± 7
88.3 ± 14.4
27.2 ± 3.9
125.8 ± 8.4
74.0 ± 8.6
67.5 ± 8.8
103.8 ± 27.4
97.0 ± 22.4
25.1 ± 7.0

0.04
0.68
0.50
0.38
0.71
0.33
0.77
0.90
0.64
0.56

S500 = 500 mg daily dose of ashwagandha; PLA = placebo.

3.1. Dietary Intake Variables
No significant main effect for time or group × time interaction effects were noted for average
calories (Time, p = 0.33, Group × Time, p = 0.70), carbohydrate (Time, p = 0.74, Group × Time, p = 0.62),
fat (Time, p = 0.07, Group × Time, p = 0.20), or protein intakes (Time, p = 0.62, Group × Time, p = 0.29),
respectively (Table 3).
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Table 3. Dietary intake data.
Between-Group Comparison
Variables

Baseline
(Week 0)

n

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

2087 ± 512
2093 ± 1171

0.54
0.45

−77 ± 200

(−483, 329)

0.70

221 ± 78
204 ± 107

0.88
0.62

12.1 ± 24

(−36.4, 60.7)

0.62

104 ± 38
115 ± 39

113 ± 42
112 ± 51

0.32
0.67

11.8 ± 11.1

(−10.6, 34.2)

0.29

78 ± 29
73 ± 32

82 ± 28
94 ± 79

0.88
0.34

−17.1 ± 13.1

(−43.7, 9.4)

0.20

Calorie Intake (kcals/day)
S500
PLA

2027 ± 568
1956 ± 808

19
19

Carbohydrate Intake (g/day)
S500
PLA

219 ± 84
214 ± 125

19
19

Protein Intake (g/day)
S500
PLA

19
19

Fat Intake (g/day)
S500
PLA

19
19

S500 = 500 mg daily dose of ashwagandha; PLA = placebo. 95% CI = 95% confidence interval of the difference
between S500 and PLA. Within p-value = Factorial ANOVA with repeated measures on time. Between-group
p-values were calculated using independent t-tests using the delta value (week 12–week 0).

3.2. Body Composition Variables
A significant group × time interaction effect (p = 0.03) was found for the DEXA android/gynoid
ratio. Delta values (week 12–week 0) were subsequently computed and assessed using independent
t-tests, along with 95% confidence intervals on the observed difference between groups. A within-group
analysis of the main effect for time revealed no change in S500 while, PLA experienced a significant
increase in DEXA-derived android/gynoid ratios. No other statistically significant outcomes were
noted for body mass or body composition variables (Table 4).
Table 4. Body composition.
Between-Group Comparison
Variables

n

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

23.8 ± 6.4
25.1 ± 7.0

23.2 ± 6.1
25.3 ± 6.5

0.25
0.49

−0.80 ± 0.57

(−1.96, 0.36)

0.17

61.9 ± 7.6
62.9 ± 8.4

62.3 ± 7.6
62.9 ± 8.4

0.43
0.91

3.95 ± 5.6

(−7.41, 1.53)

0.49

19.7 ± 7.1
21.8 ± 8.6

19.1 ± 6.3
22.0 ± 8.6

0.19
0.57

−8.9 ± 6.3

(−2.2, 3.8)

0.17

3.52 ± 1.33
3.30 ± 1.26

3.64 ± 1.39
3.21 ± 1.09

0.24
0.21

0.21 ± 0.12

(−0.03, 0.44)

0.09

0.992 ± 0.28
1.185 ± 0.31

0.99
0.001 †

(−0.09 ± 0.04)

(−0.17, −0.01)

0.03 ‡

Percent Body Fat (%)
S500
PLA

19
19

DXA Lean Mass (kg)
S500
PLA

19
19

DXA Fat Mass (kg)
S500
PLA

19
19

DXA Lean/Fat Ratio
S500
PLA

19
19

DXA Android/Gynoid Ratio
S500
PLA

19
19

0.992 ± 0.26
1.095 ± 0.29
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Table 4. Cont.
Between-Group Comparison
Variables

n

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

0.43 ± 0.36
1.02 ± 0.98

0.41 ± 0.34
0.99 ± 0.93

0.37
0.53

0.05 ± 49.1

(−99.6, 99.7)

0.99

85.5 ± 10.5
88.3 ± 14.4

84.9 ± 10.5
87.7 ± 14.3

0.52
0.58

0.03 ± 1.35

(−2.71, 2.77)

0.98

DXA Visceral Adipose Tissue (kg)
S500
PLA

19
19

Body Mass (kg)
S500
PLA

19
19

S500 = 500 mg daily dose of ashwagandha; PLA = placebo. 95% CI = 95% confidence interval of the difference
between S500 and PLA. Within p-value = Factorial ANOVA with repeated measures on time. Between-group
p-values were calculated using independent t-tests using the delta value (week 12–week 0). † indicates significant
within-group differences, ‡ indicates significant between group differences.

3.3. Visual Analog Scales
Visual analog scales were used to assess perceived recovery, soreness, and several measures of
affect. No significant group × time interactions were found for any of the assessed variables (Table 5).
Perceived recovery scores significantly improved across time in the S500 group (+14.4%, p = 0.003)
while no change was noted in the PLA group (+6.7%, p = 0.25). Similarly, perceived soreness scores
significantly increased in the PLA group (+45.6%, p = 0.04), while no change was noted in the S500
group (+18.0%, p = 0.37).
Table 5. Visual analog scales.
Between-Group Comparison
Variables

n

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

Perceived Recovery Score
S500
PLA

19
19

6.58 ± 1.22
7.00 ± 1.37

7.53 ± 1.02
7.47 ± 1.90

0.003 †
0.25

0.47 ± 0.48

(−0.51, 1.45)

0.33

19
19

6.58 ± 1.30
6.43 ± 1.64

6.75 ± 1.31
6.78 ± 1.43

0.64
0.31

−0.18 ± 0.49

(−1.18, 0.82)

0.72

19
19

7.22 ± 1.25
6.56 ± 1.67

7.61 ± 1.17
7.24 ± 1.50

0.19
0.08 †

−0.28 ± 0.47

(−1.22, 0.67)

0.55

6.46 ± 1.55
6.46 ± 1.56

7.08 ± 1.57
7.05 ± 1.62

0.18
0.13

0.04 ± 0.58

(−1.14, 1.22)

0.95

19
19

7.41 ± 1.67
7.01 ± 1.84

7.92 ± 1.40
7.59 ± 1.35

0.27
0.07 †

−0.07 ± 0.53

(−1.16, 1.01)

0.89

19
19

7.37 ± 1.86
7.23 ± 1.98

7.88 ± 2.09
7.79 ± 1.46

0.25
0.09 †

−0.06 ± 0.53

(1.13, 1.02)

0.91

19
19

3.33 ± 1.87
2.63 ± 2.19

3.93 ± 2.47
3.83 ± 2.37

0.37
0.04 †

−0.61 ± 0.83

(−2.30, 1.09)

0.47

Invigorated
S500
PLA
Mood
S500
PLA

Desire to Workout
S500
PLA

19
19

Willingness to Train
S500
PLA
Optimism
S500
PLA
Soreness
S500
PLA

S500 = 500 mg daily dose of ashwagandha; PLA = placebo. 95% CI = 95% confidence interval of the difference
between S500 and PLA. Within p-value = Factorial ANOVA with repeated measures on time. Between-group
p-values were calculated using independent t-tests using the delta value (week 12–week 0). † indicates significant
within-group differences.
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3.4. Exercise Performance
Significant group × time interaction effects were found for changes in back squat 1 RM (+18.2%
for S500 vs. +9.7% for PLA, p = 0.009; 95% CI: (2.4, 15.8 kg)) and bench press 1 RM (+13.7% for S500 vs.
+8.2% for PLA, p = 0.048; 95% CI: (0.03, 9.52 kg))—see Figures 2 and 3, respectively. Changes in the
7.5 km time trial performance were statistically significant in the S500 group (21% faster, p < 0.001),
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Table 6. Exercise performance.
Between-Group Comparison
Variables

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

977 ± 119
1020 ± 189

<0.001 †
0.18

−95.5 ± 133

(−366, 174)

0.48

1510 ± 220
1486 ± 227

0.007 †
0.12

19.2 ± 41.1

(−64.1, 102.4)

0.52

2424 ± 347
2444 ± 271

2628 ± 197
2580 ± 217

<0.001 †
0.01 †

68.5 ± 67.4

(−68.1, 205.1)

0.32

105.0 ± 30.2
103.8 ± 27.4

124.1 ± 32.0
113.9 ± 27.2

<0.001 †
<0.001 †

9.1 ± 3.3

(2.4, 15.8)

0.009 ‡

36.6 ± 10.0
44.4 ± 19.5

0.01 †
0.002 †

−4.9 ± 4.2

(−13.4, 3.5)

0.24

106.5 ± 24.7
105.0 ± 23.3

<0.001 †
<0.001 †

4.78 ± 2.34

(0.03, 9.52)

0.048 ‡

0.005 †
0.04

17.1 ± 18.8

(−21.1, 55.3)

0.37

0.007 †
0.21

30.4 ± 26.3

(−23.0, 83.8)

0.26

<0.001 †
0.03 †

2.4 ± 3.1

(−3.95, 8.69)

0.45

N

7.5 km Time Trial (seconds)
S500
PLA

19
19

1241 ± 268
1189 ± 389

Average Power All Sets Squats (Watts)
S500
PLA

19
19

1443 ± 206
1442 ± 240

Peak Power All Sets Squats (Watts)
S500
PLA

19
19

Squat 1-RM (kg)
S500
PLA

19
19

Squat Repetitions All Sets (repetitions)
S500
PLA

19
19

29.8 ± 11.7
32.7 ± 12.0

Bench Press 1-RM (kg)
S500
PLA

19
19

93.7 ± 21.3
97.0 ± 22.4

Average Bench Press Power All Sets (Watts)
S500
PLA

19
19

379 ± 101
396 ± 127

423 ± 107
423 ± 111

Peak Power Bench Press All Sets (Watts)
S500
PLA

19
19

492 ± 131
529 ± 154

548 ± 133
554 ± 156

Bench Press Repetitions Completed All Sets
S500
PLA

19
19

29.8 ± 5.3
30.8 ± 8.4

38.2 ± 9.6
36.8 ± 12.4

S500 = 500 mg daily dose of ashwagandha; PLA = placebo. 95% CI = 95% confidence interval of the difference
between S500 and PLA. Within p-value = Factorial ANOVA with repeated measures on time. Between-group
p-values were calculated using independent t-tests using the delta value (week 12–week 0). † indicates significant
within-group differences, ‡ indicates significant between group differences.

3.5. Clinical Chemistry
Significant group × time interactions were found for red blood cell count (p = 0.04), hemoglobin
(p = 0.002), hematocrit (p = 0.03), total protein (p = 0.04), and albumin (p = 0.05) (Table 7). For all
variables, values increased slightly in the PLA group, but were considered stochastic, and remained
within normal clinical limits.

Nutrients 2018, 10, 1807

13 of 18

Table 7. Serum and whole blood clinical markers of safety.
Between-Group Comparison
Variables

N

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

6.48 ± 1.40
5.68 ± 1.83

0.14
0.68

0.46 ± 0.51

(−0.56, 1.49)

0.37

5.08 ± 0.29
5.07 ± 0.36

5.08 ± 0.24
5.21 ± 0.42

0.97
0.01 †

−0.15 ± 0.07

(−0.29, −0.01)

0.04 ‡

15.5 ± 0.24
15.4 ± 0.90

15.2 ± 0.53
15.8 ± 0.94

0.03 †
0.02 †

−0.64 ± 0.19

(−1.03, −0.26)

0.002 ‡

43.5 ± 2.42
43.4 ± 2.33

43.5 ± 1.75
44.7 ± 2.87

0.85
0.01 †

−1.37 ± 0.62

(−2.63, −0.11)

0.03 ‡

87.9 ± 8.4
89.5 ± 6.3

90.8 ± 4.7
90.4 ± 5.7

0.18
0.63

2.11 ± 2.69

(−3.35, 7.56)

0.44

14.5 ± 3.55
15.1 ± 3.85

14.3 ± 3.0
14.7 ± 3.1

0.72
0.60

0.16 ± 0.91

(−1.69, 2.00)

0.86

1.01 ± 0.15
0.98 ± 0.13

1.08 ± 0.14
1.02 ± 0.13

0.03 †
0.11

0.02 ± 0.04

(−0.05, 0.10)

0.56

White blood cell count (cells/µL)
S500
PLA

19
19

5.88 ± 1.36
5.54 ± 1.50

Red blood cell count (cells/µL)
S500
PLA

19
19

Hemoglobin (g/dL)
S500
PLA

19
19

Hematocrit (%)
S500
PLA

19
19

Glucose (g/dL)
S500
PLA

19
19

Blood Urea Nitrogen (mg/dL)
S500
PLA

19
19

Creatinine (mg/dL)
S500
PLA

19
19

Blood Urea Nitrogen/Creatinine Ratio
S500
PLA

19
19

14.5 ± 3.2
15.8 ± 5.3

13.5 ± 2.9
14.8 ± 4.1

0.19
0.24

−0.05 ± 1.13

(−2.34, 2.23)

0.96

141.6 ± 1.39
141.2 ± 1.64

141.1 ± 1.24
140.5 ± 1.78

0.29
0.13

0.21 ± 0.61

(−1.02, 1.45)

0.73

4.44 ± 0.32
4.40 ± 0.22

4.33 ± 0.26
4.34 ± 0.21

0.10
0.21

−0.04 ± 0.08

(−0.20, 0.12)

0.59

101.1 ± 1.99
100.9 ± 1.70

101.2 ± 1.99
100.6 ± 1.77

0.77
0.48

0.47 ± 0.70

(−0.94, 1.89)

0.50

24.7 ± 1.77
24.1 ± 1.78

24.3 ± 1.73
23.2 ± 2.41

0.34
0.18

0.47 ± 0.77

(−1.09, 2.03)

0.54

7.36 ± 0.43
7.15 ± 0.28

7.20 ± 0.40
7.31 ± 0.33

0.16
0.12

−0.32 ± 0.14

(−0.61, −0.02)

0.04

4.80 ± 0.30
4.74 ± 0.19

4.67 ± 0.25
4.78 ± 0.20

0.04 †
0.53

−0.16 ± 0.08

(−0.33, 0.00)

0.05

Sodium (mEq/L)
S500
PLA

19
19

Potassium (mEq/L)
S500
PLA

19
19

Chloride (mEq/L)
S500
PLA

19
19

Carbon Dioxide (mEq/L)
S500
PLA

19
19

Protein (g/dL)
S500
PLA

19
19

Albumin (g/dL)
S500
PLA

19
19
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Table 7. Cont.
Between-Group Comparison
Variables

Baseline
(Week 0)

Post
(Week 12)

Within
p-Value

Mean
Difference

95% CI

p-Value

2.56 ± 0.26
2.41 ± 0.28

2.53 ± 0.25
2.53 ± 0.34

0.72
0.23

−0.15 ± 0.13

(−0.41, 0.11)

0.24

1.89 ± 0.22
2.00 ± 0.29

1.86 ± 0.21
1.93 ± 0.28

0.60
0.42

0.03 ± 0.11

(−0.19, 0.25)

0.77

0.58 ± 0.32
0.71 ± 0.45

0.59 ± 0.28
0.74 ± 0.41

0.88
0.52

−0.03 ± 0.09

(−0.21, 0.16)

0.77

64.2 ± 11.5
74.3 ± 19.9

0.46
0.85

−2.58 ± 3.5

(−9.68, 4.52)

0.47

22.8 ± 8.2
25.9 ± 8.1

0.24
0.61

−2.68 ± 2.56

(−7.88, 2.51)

0.30

22.8 ± 8.2
25.9 ± 8.1

0.88
0.24

−2.37 ± 2.40

(−7.23, 2.50)

0.33

155.2 ± 28.6
184.3 ± 43.5

0.51
0.49

−5.0 ± 5.2

(−15.5, 5.5)

0.34

80.5 ± 35.6
116.5 ± 66.

0.36
0.38

21.7 ± 17.5

(−13.8, 57.2)

0.22

0.23
0.86

−2.16 ± 1.95

(−6.11, 1.80)

0.28

0.33
0.94

1.74 ± 2.23

(−2.78, 6.27)

0.44

0.59
0.33

−6.19 ± 5.34

(−17.0, 4.6)

0.25

N

Globulin (g/dL)
S500
PLA

19
19

Albumin/Globulin Ratio
S500
PLA

19
19

Bilirubin (mg/dL)
S500
PLA

19
19

Alkaline Phosphatase (U/L)
S500
PLA

19
19

66.4 ± 14.4
73.9 ± 21.4

Aspartate Aminotransferase (U/L)
S500
PLA

19
19

24.3 ± 9.2
24.8 ± 7.8

Alanine Aminotransferase (U/L)
S500
PLA

19
19

20.6 ± 9.1
24.8 ± 7.8

Total Cholesterol (mg/dL)
S500
PLA

19
19

157.2 ± 31.9
181.3 ± 44.9

Triglycerides (mg/dL)
S500
PLA

19
19

72.7 ± 21.7
130.4 ±
114.8

High Density Lipoprotein Cholesterol (mg/dL)
S500
PLA

19
19

53.3 ± 10.8
47.7 ± 7.2

51.4 ± 11.5
47.9 ± 7.7

Very Low Density Lipoprotein Cholesterol (mg/dL)
S500
PLA

19
19

14.4 ± 4.5
21.8 ± 14.2

16.1 ± 7.0
23.3 ± 13.4

Low Density Lipoprotein Cholesterol (mg/dL)
S500
PLA

19
19

89.4 ± 30.5
107.1 ± 34.3

87.8 ± 25.3
113.2 ± 36.6

S500 = 500 mg daily dose of ashwagandha; PLA = placebo. 95% CI = 95% confidence interval of the difference
between S500 and PLA. Within p-value = Factorial ANOVA with repeated measures on time. Between-group
p-values were calculated using independent t-tests using the delta value (week 12–week 0). † indicates significant
within-group differences, ‡ indicates significant between group differences.

4. Discussion
Using a randomized, double-blind, placebo-controlled design, the purpose of the present study
was to assess the impact of supplementing with an extract of roots and leaves of the ashwagandha
plant (Sensoril® ) on adaptations to strength training in recreationally active, healthy men. The primary
findings of this investigation are that significantly greater improvements in both lower-body and
upper-body maximal strength occurred when participants were supplementing with a 500 mg dose
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of ashwagandha as compared to placebo. In addition, ashwagandha supplementation significantly
attenuated increases in the android/gynoid ratio as measured by DEXA, and only the ashwagandha
group experienced statistically significant improvements in average squat power, peak bench press
power, 7.5 km time trial performance, and perceived recovery scores.
Primary outcomes were defined a priori as changes in maximal strength. Based on the existing,
yet somewhat limited literature, we hypothesized that ashwagandha supplementation would improve
maximal strength to a greater extent when compared to changes seen with placebo. Results from the
present study indicated that maximal lower-body and upper-body strength levels, as assessed with
a 1-RM maximum squat and bench press, respectively, experienced significantly greater increases
after supplementing with a 500 mg dose of ashwagandha in comparison to changes seen in subjects
taking a placebo. In addition, average squat power and peak bench press power only increased
in the group that supplemented with ashwagandha (S500). Consequently, these results provide
additional support that indicate the ability of ashwagandha to improve muscular performance during
resistance training. Previously, Sandhu and colleagues [6] reported that ashwagandha supplementation
in 40 healthy participants significantly improved barbell velocity, muscular power, and VO2 Max.
Raut et al. [8] used a less rigorous, open-label design in 18 healthy volunteers, and also reported an
increase in strength. Furthermore, Wankhede and colleagues [9] supplemented 57 young, but untrained
male participants for eight weeks with either 600 mg of ashwagandha (root extract) or placebo
while completing a resistance training program, and also reported significantly greater increases in
lower-body and upper-body strength. From a mechanistic perspective, the observed improvements in
muscular strength while supplementing with ashwagandha are not well understood. Several levels
of changes (intramuscular, central nervous, inside the tendon) can occur that can lead to an increase
in force production. Unfortunately, the present study and others have not employed approaches to
further determine these changes. Future research should employ ultrasound, electromyography, and
mechanomyography (MMG) techniques to better understand the neuromuscular reasons for why
strength increases have been reported in the ashwagandha literature.
In addition to the performance outcomes, other published reports have highlighted the ability of
ashwagandha supplementation to improve various measures of body composition [6,8,9]. For example,
Wankehede and colleagues [9] reported significantly greater increases in arm and chest circumference,
and greater reductions in body fat percentage (using bioimpedance analysis) in those participants who
were supplementing with ashwagandha when compared to a placebo. Results from the present study
failed to report any significantly greater improvement in body fat percentage, fat-free mass or fat mass
as assessed using a more rigorous assessment tool (e.g., DEXA). A significant group × time interaction
(Table 4) was found for the android/gynoid ratio compared to the placebo. The android/gynoid ratio
is a metric generated by the DEXA software upon the analysis of each DEXA scan. Pre-defined regions
are outlined from each scan, and the DEXA software calculates the total tissue mass found in an android
region (trunk) and a gynoid region (hips), and calculates the ratio between these regions. The metric
is considered to be a crude marker of visceral fat accumulation. In this respect, an increase in the
android/gynoid ratio would be viewed as a less favorable change, due to the known increase in health
risks associated with carrying more weight in the torso versus the hips/gluteal region (e.g., insulin
resistance, dyslipidemias, etc.) [20–22]. In this study, individuals supplementing with ashwagandha
experienced no change in this ratio, while participants who supplemented with a placebo experienced
a significant increase in the ratio. While this is intriguing, the lack of other associated changes with
measured body composition variables makes this finding challenging to interpret. Thus, more research
is needed to better understand the potential impact that ashwagandha may have on initiating changes
in body composition parameters, particularly any repartitioning of adipose tissue to central regions.
Future research should explore assessing changing in various inflammatory biomarkers to identify
potential mechanistic considerations for these changes. When viewed collectively, some might question
the positive improvements in strength alongside the lack of change seen with lean or fat-free mass
levels in the present study. These outcomes, however, have been documented previously. For example,
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Ahtiainen and colleagues [23] completed a retrospective analysis of 287 individuals between the ages
of 19–78 years who had previously performed a resistance training program. As expected, a positive
correlation (r = 0.157, p = 0.008, n = 283) was found between the two responses, but these outcomes
varied widely and thus highlight the ability of strength increases to occur without measurable changes
in muscle mass. Most importantly, these outcomes clearly point to the need for future studies to more
closely investigate the changes seen at the neuromuscular level using techniques such as ultrasound,
EMG (electromyography), and MMG (mechanomyography).
In addition to assessing changes in muscular performance and body composition, we also assessed
aerobic exercise performance (via cycling) as well as several self-perception scales of recovery and affect.
In line with a previous study that reported significant improvements in VO2 Max after supplementing
with ashwagandha [6], a statistically significant improvement in 7.5 km cycling time trial performance
was noted in the ashwagandha-supplemented group (p < 0.001) in the present study while no such
change was identified in the placebo group (p = 0.18). Of note, the group × time interaction effect
for this variable did not cross statistically significant thresholds (p = 0.48). Additionally, although
no significant changes in affect (using various VAS) were found, subjects who supplemented with
ashwagandha did demonstrate significant improvements in perceived recovery scores, while no
such change was observed in the placebo group. These changes are consistent with previous work,
indicating that ashwagandha may help to improve soreness [9], stress [4], and anxiety [1]. Overall,
much more work is needed to understand to what extent the type of exercise training, the quality of
the subject/athlete, and the exercise stimulus might influence various study outcomes.
This study has several strengths. First, the 12-week supplementation and resistance training
program is one of the longest studies to date with any ashwagandha product. Next, participants in
this study were already active and participating in various forms of exercise, as opposed to being
unaccustomed to physical activity. This is important, as several researchers have identified the impact
of training status on adaptations seen from resistance training and other forms of exercise. Finally,
this study employed a randomized, double-blind, placebo-controlled design, a gold standard for
clinical research.
We also acknowledge the limitations of this study. While all participants were instructed to follow
strict pre-exercise guidelines of rest and fasting, the ability to detect additional changes in performance
may have been influenced by study participant’s compliance to these directives. Moreover, while the
present study did not overtly seek to maximize hypertrophy adaptations to training, our subjects’ total
energy and protein intakes may have undermined their ability to attain more pronounced changes in
muscle mass. As an example, relative energy intake was approximately 23.5–25 kcals per kilogram
of body mass, and protein intake was ~1.2–1.3 g of protein per kilogram of body mass/day. While
potentially adequate, both of these values are lower than recommended amounts to optimize changes
in lean mass during resistance exercise training [24,25]. In addition, while weekly contact with subjects
was used to gauge compliance with the exercise program, workouts were not strictly supervised by
study personnel, and this could have impacted the changes we observed in our study.
Future studies should attempt to more thoroughly control diet, and they include measurements of
appetite. In addition, we recommend measuring biomarkers of cardiovascular and metabolic disease
risk, including inflammatory cytokines along with utilizing -omic technologies to identify potential
changes in novel biomarkers that might assist in potentially establishing an evidence base for this
Ayurvedic herb. Finally, methods that permit an examination of motor unit/nervous system activation
should be used to help explain the beneficial changes in strength, as noted by us and other authors.
In conclusion, 12 weeks of supplementation with a 500 mg dose of an ashwagandha extract
from the plants and leaves (Sensoril® ), in combination with a progressive, heavy resistance-training
program, resulted in significant improvements in maximal lower-body and upper-body strength, and
significantly attenuated increases in the android/gynoid ratio. In addition, only the ashwagandha
group experienced statistically significant improvements in average squat power, peak bench press
power, 7.5 km time trial performance, and perceived recovery scores.
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